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Abstract
We performed a randomized, controlled trial in 30 HIV-infected participants to either continue
tenofovir/emtricitabine/efavirenz (Continuation Group) or switch to tenofovir/emtricitabine/
raltegravir (Switch Group) for 24 weeks. There were no significant differences in the changes in
flow-mediated dilation, 25(OH)vitamin D, or parathyroid hormone levels. Total cholesterol, high
sensitivity C-reactive protein, serum alkaline phosphatase, sCD14 levels, and renal function
significantly declined in the Switch Group compared to the Continuation Group; however,
sCD163 levels significantly increased in the Switch Group. These findings suggest that raltegravir
is not inherently more beneficial to endothelial function compared to efavirenz but may impact
renal function and monocyte activation.
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INTRODUCTION
As HIV-infected patients are achieving nearly normal life expectancies with the use of
potent antiretroviral therapies (ART), cardiovascular disease (CVD) has emerged as a
leading cause of morbidity and mortality.1 One mechanism by which HIV infection or its
therapies may lead to this increased risk in CVD is through impairment of the vascular
endothelium. We recently completed a 12 month observational study in which we assessed
flow-mediated dilation (FMD), a measure of in vivo endothelial function, over 12 months in
HIV-infected patients initiating their first ART regimen.2 Although FMD did not
significantly change in the entire group, we observed worsening FMD with efavirenz (EFV)-
based treatment and an improvement in FMD in those receiving protease inhibitors. The
large reduction in FMD in the EFV group was primarily in those receiving the combination
of tenofovir (TDF), emtricitabine (FTC), and EFV. Another recent study also suggested that
initiation of EFV-based regimens, most of which also incorporated TDF, also led to a
decrease in FMD.3 Although large, observational studies, such as the Data Collection on
Adverse Events of Anti-HIV Drugs (D:A:D) study, have suggested no increase in risk of
myocardial infarctions with use of non-nucleoside reverse transcriptase inhibitors such as
EFV,4 in the randomized trial ACTG 5202, the use of TDF/FTC/EFV was associated with
numerically more acute ischemic events compared to other once-daily regimens, including
those incorporating abacavir.5 Taken together, these findings suggest a potentially adverse
effect of EFV, especially the combination of TDF/FTC/EFV, on cardiovascular health.
One possible mechanism for an adverse effect of TDF/FTC/EFV on CVD risk may involve
the calcium-phosphorus homeostasis axis, with reductions of circulating vitamin D levels
with EFV and/or increases in parathyroid hormone levels with TDF, respectively; both
abnormalities have been associated with endothelial dysfunction.6–9 If secondary
hyperparathyroidism due to EFV, especially when coupled with TDF, is the cause of
increased CVD risk with this specific combination, then perhaps removing the EFV
component of an ART regimen would be beneficial. Therefore, we conducted a randomized
trial assessing the effects of switching HIV-infected patients receiving TDF/FTC/EFV to
TDF/FTC/Raltegravir (RAL) on endothelial function and markers of bone mineral
metabolism.
METHODS
Study design
We performed a single-center, open-label, randomized, controlled trial in 30 HIV-infected
study participants who had been receiving TDF/FTC/EFV as their initial HIV treatment
regimen (ClinicalTrials.gov NCT01270802). Participants were randomized 1:1 to continuing
treatment with TDF/FTC/EFV (‘Continuation Group’) vs. switching their regimen to
TDF/FTC plus RAL 400 mg twice daily (‘Switch Group’). Study procedures were
performed at entry, week 8, and week 24. Randomization in varying sized blocks (2, 4, or 6)
was employed for this study. This trial was approved by the Indiana University Institutional
Review Board. All participants provided written, informed consent prior to screening.
Merck & Co. provided both an unrestricted research grant in support of this trial and
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raltegravir for those assigned to the Switch Group but had no role in the design, conduct, or
reporting of the study results.
Study population
Participants were recruited from the HIV outpatient clinics associated with the Indiana
University Health medical system. Primary inclusion criteria included documented HIV-1
infection, age ≥18 years, receipt of TDF/FTC/EFV as their initial treatment regimen for at
least one year prior to screening, and having both an HIV RNA level <50 copies/mL at
screening and also between one and six months prior to screening. Major exclusion criteria
included diagnosed cardiovascular disease, diabetes, uncontrolled hypertension (screening
systolic blood pressure >160 mm Hg or diastolic pressure > 90 mm Hg), other systemic
inflammatory disease (although hepatitis B or C co-infection was allowed); estimated
creatinine clearance <50 mL/min; or use of lipid-lowering drugs.
Study procedures
Participants were required to fast and not smoke for at least 8 hours prior to all study
procedures. FMD and nitroglycerin-mediated dilation (NTGMD) studies were performed
using an Acuson CV70 ultrasound machine at all study visits according to recommended
guidelines 10 by a single registered vascular ultrasonographer. Images were interpreted by a
blinded, single investigator (S.K.G.) using Access Point Web software (Freeland Systems,
Westminster, CO). The intraclass correlations for reproducibility for baseline diameter and
FMD measured twice in 12 healthy volunteers in our laboratory under these conditions were
0.97 and 0.73, respectively.
Circulating inflammatory markers [high sensitivity C-reactive protein (hsCRP), serum
interleukin-6 (IL-6), soluble tumor necrosis factor-α receptors I and II (sTNFRI, sTNFRII),
monocyte chemoattractant protein-1 (MCP-1), interferon-γ-inducible protein-10 (IP-10)],
endothelial markers [soluble vascular cell adhesion molecule-1 (sVCAM-1), asymmetric
dimethylarginine (ADMA)], markers of monocyte/macrophage activation [soluble CD14
(sCD14), soluble CD163 (sCD163)], and metabolic markers [serum cystatin C, lipid
fractions, insulin] were measured at the University of Vermont Laboratory for Clinical
Biochemistry Research. Serum calcium, phosphorus, parathyroid hormone (PTH),
25(OH)vitamin D, and fibroblast growth factor-23 (FGF-23) were measured in the research
laboratory of one investigator (S.M.M.). All of these markers were measured in batch from
archived frozen samples kept at −80°C. Serum glucose, creatinine, and CD4 cell count along
with urine albumin, protein, phosphorus, and creatinine levels (measured on fasting morning
urine samples) were assessed at the Indiana University Health clinical laboratory. Renal
function was estimated as creatinine clearance with the Cockcroft-Gault equation11 and as
glomerular filtration rates (eGFR) using the 2009 CKD-EPI equation,12 the 2012 CKD-EPI
cystatin C equation,13 and the 2012 CKD-EPI combined cystatin C-creatinine equation.13
The homeostasis model assessment-insulin resistance (HOMA-IR) was used to estimate
insulin resistance from fasting glucose and insulin measures.14
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Statistical analysis
We assumed that the declines in FMD seen with TDF/FTC/EFV in our previous study 2
would fully reverse with switch to TDF/FTC/RAL. Thus, the clinically relevant effect size
to be detected for FMD change was +3.12% with a standard deviation of 4% in those
switching from EFV to RAL. Using a two-sample, independent, two-tailed t-test with 5%
type I error and 20% type II error, a sample size of 13 per group would be needed to find a
difference in FMD between groups. Allowing for a 10% dropout rate, we planned to recruit
15 subjects per group.
Categorical variables were examined using Fisher’s exact test. We employed Student’s t-test
for comparisons of continuous measures as we found no evidence of violation of the
normality assumption for these variables. Of note, serum glucose, calcium, PTH,
25(OH)vitamin D, FGF-23, hsCRP, IL-6, triglycerides, MCP-1, HIV-1 RNA, HOMA-IR,
urine albumin/creatinine, urine protein/creatinine, and urine calcium/creatinine required
logarithmic transformation to approximate normal distributions prior to such analysis.
Wilcoxon rank sum tests were also performed for log-transformed variables, and the same
significance levels were obtained (data not shown).
Analyses were performed as intention to treat but without corrections for multiple testing for
the secondary analyses. Two-sided P-values <0.05 were considered statistically significant.
All analyses were performed in SAS 9.3 (SAS Inc., Cary, NC).
RESULTS
Study cohort characteristics
Enrollment into this trial occurred between April 2011 and May 2012. Thirty-two persons
screened for enrollment. Two of these failed screening for having screening HIV-1 RNA
levels >50 copies/mL; the remaining 30 were equally randomized into the two study groups.
Of these, one participant in the Continuation Group was removed at Entry for confirmed
virologic failure (repeat HIV-1 RNA >50 copies/mL). One participant in the Continuation
Group withdrew from participation between Entry and week 8 due to moving out of area.
One participant in the Switch Group was lost to follow-up between week 8 and week 24.
Thus, 13 and 15 participants, respectively, were assessed in the Continuation Group and
Switch Group at week 8 whereas 13 and 14 participants, respectively, were assessed at
Week 24. Table 1 shows the well-balanced baseline characteristics of the 30 enrolled
participants.
Changes in vascular measures
The vascular results are shown in Table 2 and in Table 3 (Supplemental Digital Content 1,
which shows additional secondary data comparisons). There were no significant changes in
FMD, ADMA, or sVCAM-1 between groups at either Week 8 or Week 24.
Changes in bone mineral markers
There were no significant differences in the changes between groups in PTH,
25(OH)vitamin D, or FGF-23 levels at either week 8 or week 24 (Tables 2 and 3,
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Supplemental Digital Content 1). Alkaline phosphatase levels significantly decreased more
in the Switch Group than in the Continuation Group at week 24.
Changes in metabolic markers
Total cholesterol levels decreased significantly at both weeks 8 and 24 in the Switch Group
compared to the Continuation Group (Table 2). There was also a significant decrease in the
Switch Group in LDL-C at week 8, but there no significant differences between groups in
LDL-C at week 24.
Changes in inflammatory markers
As shown in Table 2, hsCRP levels and sCD14 levels decreased significantly more so in the
Switch Group than the Continuation Group at weeks 8 and 24. There was a significant
increase in sCD163 in the Switch Group compared to the Continuation Group at week 24.
There were no significant differences between groups in the other inflammatory markers
(see Table 3, Supplemental Digital Content 1).
Changes in renal function markers
Interestingly, we found significant decreases in creatinine clearance at week 24 (but not at
week 8) and in all three GFR estimates in the Switch Group compared to the Continuation
Group at week 8 with significant differences in eGFR persisting using just the two 2012
CKD-EPI equations at week 24 (Table 2). However, there were no significant differences
between groups in the changes in urine albumin/creatinine or protein/creatinine ratios at
either time point.
Safety
There were no safety concerns in this trial apart from the one participant in the Continuation
Group who was removed after fulfilling virologic failure criteria at Entry; there were no
virologic failures in the Switch Group. There were no significant differences in numbers or
types of adverse events between Groups. None of these adverse events were treatment
limiting.
DISCUSSION
In HIV-infected study participants receiving TDF/FTC/EFV as their first regimen and with
suppressed viremia, we did not find that switching the EFV component of this regimen to
RAL resulted in changes in endothelial function over 24 weeks. These data do not support
the hypothesis that RAL is intrinsically more beneficial to the endothelium compared to
EFV. Our results are similar to those found by Masia et al15 who also found no change in
FMD by switching from a protease inhibitor to RAL or by Hatano et al16 who found no
improvement in FMD after RAL intensification.
We had speculated that any potential changes in FMD with switch from EFV to RAL could
be due to changes in vitamin D or PTH.17 However, none of the serum or urine bone
mineral markers changed significantly apart from a reduction in serum alkaline phosphatase
in the Switch Group as expected.18
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Total cholesterol levels improved in the Switch Group, which corroborates findings from
previous studies assessing switches from protease inhibitors15, 19, 20 or EFV20 to RAL.
Similar findings in ART-naïve studies comparing RAL to EFV showed less effects of RAL
on lipid profiles.21
We surprisingly found declines in renal function, both in estimated creatinine clearance and
in eGFR, in the Switch Group compared to the Continuation Group. The differences
between groups in eGFR we observed were approximately 10 mL/min/1.732, which are
similar to the declines found in those initiating TDF.5, 22, 23 The integrase inhibitor
dolutegravir has been reported to increase serum creatinine through inhibition of creatinine
secretion via the human organic cation transporter 2 (hOCT2) in the renal proximal tubule
but does not lead to actual declines in directly measured GFR.24 This inhibition of hOCT2
should not lead to changes in serum cystatin C. As such, the increases in both cystatin C and
creatinine with RAL in this study may suggest a true negative effect on glomerular function.
The mechanism by which RAL may worsen renal function in those who are virologically
suppressed is not clear. RAL decreases circulating tenofovir concentrations, so a drug
interaction leading to tenofovir nephrotoxicity is unlikely. In addition, blood pressures did
not change significantly between groups (data not shown).
Regarding the inflammatory markers assessed in this study, hsCRP levels significantly
decreased with switch to RAL compared to continuation with EFV, which is in contrast to
the findings by Lake et al who found no change in hsCRP in their trial of protease inhibitor
switch to RAL among women with central obesity.20 We also explored potential changes in
sCD14 and sCD163 as markers of monocyte activation with switch to RAL. Greater sCD14
levels have been linked to an increased risk of death25 while higher sCD163 levels have
been associated with worsening inflammatory atherosclerotic disease in those with HIV
infection.26, 27 Similar to our results, a greater reduction in sCD14 with TDF/FTC/RAL
compared to non-RAL-based regimens has been previously reported in ART-naïve
patients.28 It is possible that the increased penetration of RAL into gut tissue29 may lead to
decreased viral replication in this reservoir with consequent reductions in bacterial
translocation and the monocyte-secreted lipopolysaccharide receptor sCD14. Similar to
sCD14, circulating sCD163 levels are increased by lipopolysaccharide and other
inflammatory triggers,30 so it is not clear why switching from EFV to RAL would lead to an
apparently paradoxical increase in sCD163.
Limitations to our study should be acknowledged. This study design was open-label as a
blinded study with matching placebos was considered too difficult to implement given the
differences in dosing schedules between EFV and RAL. We believe this limitation was
somewhat mitigated as the vascular ultrasound readings were blinded. We also acknowledge
that the sample size was small, although it was based on our previously published data for
the primary endpoint of change in FMD. It is unlikely that we would have found clinically
meaningful differences between groups in change in FMD with larger sizes given that the
minor changes observed. Although the reproducibility of FMD in our laboratory appears
modest, the technique in our hands actually compares quite favorably, or even better than,
those of other groups.31, 32 Of note, the high variability of FMD was accounted for in our
sample size estimate and, as such, likely would not have led to the negative findings. We do
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acknowledge that it is certainly possible that the study duration was too short to detect
changes in FMD and several of the biomarkers. We also performed numerous statistical tests
without adjustment for these multiple comparisons, so we caution that some significant
differences, especially in regards to the differential findings related to the monocyte
activation markers, may have been found by chance. However, the reductions in renal
function with RAL were found using two different markers, namely creatinine and cystatin
C, and, thus, this finding is more likely to be true. Overall, our results should be considered
hypothesis-generating with additional research required to determine the mechanisms
underlying the potentially negative effects of RAL on renal function along with the long-
term benefits and risks of using raltegravir-based regimens.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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TABLE 1
Baseline Characteristics of the Study Groups
Characteristic Continuation Group (N=15) Switch Group (N=15)
Age, yrs 38 (12.0) 39 (10.6)
Male sex 13 (87%) 14 (93%)
Black race 8 (53%) 10 (67%)
Hispanic ethnicity 0 (0%) 0 (0%)
Current smoker 8 (53%) 9 (60%)
Active hepatitis B 2 (13%) 2 (13%)
Active hepatitis C 1 (7%) 1 (7%)
Weight, kg 88.2 (17.3) 84.7 (17.9)
Body mass index, kg/m2 28.2 (5.5) 27.6 (6.3)
Baseline brachial artery diameter, cm 0.43 (0.07) 0.42 (0.04)
Data presented as mean (standard deviation) or numbers (percent); active hepatitis B defined as having a positive surface antigen on record or at
screening; active hepatitis C defined as having a positive antibody on record or at screening; seasonality data based on those who completed the
trial (13 in the Continuation Group and 14 in the Switch Group)
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